<DOC>
	<DOCNO>NCT00650546</DOCNO>
	<brief_summary>We hypothesize exenatide ( Byetta ) , GLP-1 agonist administer subcutaneously 24-28 week improve liver histology diabetic patient biopsy-proven NASH .</brief_summary>
	<brief_title>Role Exenatide NASH-a Pilot Study</brief_title>
	<detailed_description>Eight adult patient know type 2 DM ( Diabetic ) biopsy-proven NAFLD treat 5-10 mcg subcutaneous exenatide 28 week . Liver histology assess use NAFLD Activity Score ( NAS ) prior therapy 28 week therapy . We use follow criterion define primary outcome : ( ) worsen fibrosis score , ( ii ) improve score least one point hepatocyte ballooning , ( iii ) either ( ) improvement NAS 2 point spread across least two three NAS component , ( b ) post-treatment NAS equal great 3 .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Well document NASH base clinical histological criterion . Liver biopsy must obtain within 12months prior initiation study . Subjects must know diabetes ( either diet control Metformin sulfonylurea glyburide glipizide ) . Subjects must 18 year older . Coexisting etiology chronic liver disease ( hepatitis B C , autoimmune hemochromatosis , etc. ) . Clinical histological evidence cirrhosis . Alanine aminotransferase aspartate aminotransferase &gt; 300 IU/L . Uncontrolled diabetes ( hemoglobin A1C great equal 9 % ) . Insulin TZD dependant DM . Known human immunodeficiency virus infection . Current history significant alcohol consumption within past 5 year . Significant alcohol consumption define &gt; 20 grm/day female &gt; 30 grms/day male alcohol consumption satisfactorily quantify . Serum creatinine great equal 2 mg/dl . Active , serious medical disease ( cardiac , renal , pulmonary , dermatologic , psychiatric illness ) likely life expectancy le 5 year . Current previous malignancy expect life expectancy le 5years ( basal cell cancer skin ) . Use drug historically associate NASH . Histological evidence malignancy , 4+ iron deposition , type liver disease . Active substance abuse , alcohol , inhale injection drug previous one year . Known intolerance allergy exenatide ( Byetta ) . History neuroglycopenia . Women childbearing potential must negative pregnancy test prior start study willing avoid pregnancy study period . Women must nurse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Non-alcoholic steatohepatitis</keyword>
	<keyword>NASH</keyword>
</DOC>